Who will benefit most from hydrogel rectum spacer implantation in prostate cancer radiotherapy? A model-based approach for patient selection

Radiotherapy and Oncology

Volumn 121, Issue 1, 2016, Pages 118-123

  Vanneste, Ben G L ^a   Hoffmann, Aswin L ^a,b,c   van Lin, Emile N ^a   Van De Voorde, Lien ^a   Pinkawa, Michael ^d   Lambin, Philippe ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b INSTITUTE OF ION BEAM PHYSICS AND MATERIALS RESEARCH   (Germany)

^c UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^d UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Patient selection; Prostate cancer; Radiotherapy; Rectum spacer; Toxicity prediction

Indexed keywords

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; FECES INCONTINENCE; GASTROINTESTINAL TOXICITY; HUMAN; HYDROGEL ORGAN SPACER; IMAGE ANALYSIS; IMPLANTABLE RECTUM SPACER; INTENSITY MODULATED RADIATION THERAPY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT SELECTION; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE DISTRIBUTION; RECTUM HEMORRHAGE; RISK FACTOR; TREATMENT PLANNING; ADMINISTRATION AND DOSAGE; ANATOMY AND HISTOLOGY; BIOLOGICAL MODEL; DEVICES; DIAGNOSTIC IMAGING; FECAL INCONTINENCE; GASTROINTESTINAL HEMORRHAGE; HYDROGEL; MIDDLE AGED; NOMOGRAM; PROCEDURES; PROSTATIC NEOPLASMS; RADIATION INJURIES; RADIATION RESPONSE; RADIOTHERAPY PLANNING SYSTEM; RECTUM; VERY ELDERLY;

HYDROGEL;

AGED; AGED, 80 AND OVER; FECAL INCONTINENCE; GASTROINTESTINAL HEMORRHAGE; HUMANS; HYDROGEL; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; NOMOGRAMS; PATIENT SELECTION; PROSTATIC NEOPLASMS; RADIATION INJURIES; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, INTENSITY-MODULATED; RECTUM;

EID: 84992664074     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2016.08.026     Document Type: Article

References (42)

1. [1] Fonteyne, V., Ost, P., Vanpachtenbeke, F., et al. Rectal toxicity after intensity modulated radiotherapy for prostate cancer: which rectal dose volume constraints should we use?. Radiother Oncol 113 (2014), 398–403.
2. [2] Musunuru, H.B., Quon, H., Davidson, M., et al. Dose-escalation of five-fraction SABR in prostate cancer: toxicity comparison of two prospective trials. Radiother Oncol 118 (2016), 112–117.
3. [3] Vanneste, B.G., Van De Voorde, L., de Ridder, R.J., Van Limbergen, E.J., Lambin, P., van Lin, E.N., Chronic radiation proctitis: tricks to prevent and treat. Int J Colorectal Dis 30 (2015), 1293–1303.
4. [4] Smeenk, R.J., Van Lin, E.N.J.T., Application of anorectal sparing devices in prostate radiotherapy. Radiother Oncol 106 (2013), 155–156.
5. [5] Pinkawa, M., Corral, N.E., Caffaro, M., Application of a spacer gel to optimize three-dimensional conformal and intensity modulated radiotherapy for prostate cancer. Radiother Oncol 100 (2011), 436–441.
6. [6] Melchert, C., Gez, E., Bohlen, G., et al. Interstitial biodegradable balloon for reduced rectal dose during prostate radiotherapy: results of a virtual planning investigation based on the pre- and post-implant imaging data of an international multicenter study. Radiother Oncol 106 (2013), 210–214.
7. [7] Prada, P.J., Fernández, J., Martinez, A.A., et al. Transperineal injection of hyaluronic acid in anterior perirectal fat to decrease rectal toxicity from radiation delivered with intensity modulated brachytherapy or EBRT for prostate cancer patients. Int J Radiat Oncol Biol Phys 69 (2007), 95–102.
8. [8] Noyes, W.R., Hosford, C.C., Schultz, S.E., Human collagen injections to reduce rectal dose during radiotherapy. Int J Radiat Oncol Biol Phys 82 (2012), 1918–1922.
9. [9] Wilder, R.B., Barme, G.A., Gilbert, R.F., et al. Cross-linked hyaluronan gel reduces the acute rectal toxicity of radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 77 (2010), 824–830.
10. [10] Uhl, M., Van Triest, B., Eble, M.J., Weber, D.C., Herfarth, K., De Weese, T.L., Low rectal toxicity after dose escalated IMRT treatment of prostate cancer using an absorbable hydrogel for increasing and maintaining space between the rectum and prostate: results of a multi-institutional phase II trial. Radiother Oncol 106 (2013), 215–219.
11. [11] Song, D.Y., Herfarth, K.K., Uhl, M., et al. A multi-institutional clinical trial of rectal dose reduction via injected polyethylene–glycol hydrogel during intensity modulated radiation therapy for prostate cancer: analysis of dosimetric outcomes. Int J Radiat Oncol Biol Phys 87 (2013), 81–87.
12. [12] Strom, T.J., Wilder, R.B., Fernandez, D.C., et al. A dosimetric study of polyethylene glycol hydrogel in 200 prostate cancer patients treated with high-dose rate brachytherapy ± intensity modulated radiation therapy. Radiother Oncol 111 (2014), 126–131.
13. [13] Mariados, N., Sylvester, J., Shah, D., et al. Hydrogel spacer prospective multicenter randomized controlled pivotal trial: dosimetric and clinical effects of perirectal spacer application in men undergoing prostate image guided intensity modulated radiation therapy. Int J Radiat Oncol Biol Phys 92 (2015), 971–977.
14. [14] Vanneste, B.G., Pijls-Johannesma, M., Van De Voorde, L., et al. Spacers in radiotherapy treatment of prostate cancer: is reduction of toxicity cost-effective?. Radiother Oncol 114 (2015), 276–281.
15. [15] Lambin, P., van Stiphout, R.G., Starmans, M.H., et al. Predicting outcomes in radiation oncology-multifactorial decision support systems. Nat Rev Clin Oncol 10 (2013), 27–40.
16. [16] Valdagni, R., Rancati, T., Fiorino, C., et al. Development of a set of nomograms to predict acute lower gastrointestinal toxicity for prostate cancer 3D-CRT. Int J Radiat Oncol Biol Phys 71 (2008), 1065–1073.
17. [17] Valdagni, R., Kattan, M.W., Rancati, T., et al. Is it time to tailor the prediction of radio-induced toxicity in prostate cancer patients? Building the first set of nomograms for late rectal syndrome. Int J Radiat Oncol Biol Phys 82 (2012), 1957–1966.
18. [18] Pinkawa, M., Piroth, M.D., Holy, R., et al. Quality of life after intensity-modulated radiotherapy for prostate cancer with a hydrogel spacer. Matched-pair analysis. Strahlenther Onkol 188 (2012), 917–925.
19. [19] D'Amico, A.V., Whittington, R., Malkowicz, S.B., et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280 (1998), 969–974.
20. [20] Makarov, D.V., Trock, B.J., Humphreys, E.B., et al. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology 69 (2007), 1095–1101.
21. [21] Bratengeier, K., Meyer, J., Flentje, M., Pre-segmented 2-Step IMRT with subsequent direct machine parameter optimisation – a planning study. Radiat Oncol, 3, 2008, 38.
22. [22] Pollack, A., Zagars, G., Starkschall, G., et al. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 53 (2002), 1097–1105.
23. [23] Lawton, C., Michalski, J., El-Naqa, I., et al. RTOG GU radiation oncology specialists reach consensus on pelvic lymph node volumes for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 74 (2009), 383–387.
24. [24] Al-Mamgani, A., van Putten, W.L., Heemsbergen, W.D., et al. Update of Dutch multicenter dose escalation trial of radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 72 (2008), 980–988.
25. [25] Zelefsky, M.J., Levin, E.J., Hunt, M., et al. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 70 (2008), 1124–1129.
26. [26] Kuban, D.A., Tucker, S.L., Dong, L., et al. Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 70 (2008), 67–74.
27. [27] Ghadjar, P., Jackson, A., Spratt, D.E., et al. Patterns and predictors of amelioration of genitourinary toxicity after high-dose intensity-modulated radiation therapy for localized prostate cancer: implications for defining postradiotherapy urinary toxicity. Eur Urol 64 (2013), 931–938.
28. [28] Aluwini, S., Pos, F., Schimmel, E., et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial. Lancet Oncol 16 (2015), 274–283.
29. [29] Fiorino, C., Valdagni, R., Rancati, T., Sanguineti, G., Dose-volume effects for normal tissues in external radiotherapy: pelvis. Radiother Oncol 93 (2009), 153–167.
30. [30] Mok, G., Benz, E., Vallee, J.P., Miralbell, R., Zilli, T., Optimization of radiation therapy techniques for prostate cancer with prostate-rectum spacers: a systematic review. Int J Radiat Oncol Biol Phys 90 (2014), 278–288.
31. [31] Pinkawa, M., Spacer application for prostate cancer radiation therapy. Future Oncol 10 (2014), 851–864.
32. [32] West, C., Azria, D., Chang-Claude, J., et al. The REQUITE project: validating predictive models and biomarkers of radiotherapy toxicity to reduce side-effects and improve quality of life in cancer survivors. Clin Oncol (R Coll Radiol) 26 (2014), 739–742.
33. [33] West, C.M., Barnett, G.C., Genetics and genomics of radiotherapy toxicity: towards prediction. Genome Med, 3, 2011, 52.
34. [34] van Gisbergen, M.W., Voets, A.M., Starmans, M.H., et al. How do changes in the mtDNA and mitochondrial dysfunction influence cancer and cancer therapy? Challenges, opportunities and models. Mutat Res Rev Mutat Res 764 (2015), 16–30.
35. [35] Fachal, L., Gómez-Caamaño, A., Barnett, G.C., et al. A three-stage genome-wide association study identifies a susceptibility locus for late radiotherapy toxicity at 2q24.1. Nat Genet 46 (2014), 891–894.
36. [36] Dörr, W., Hendry, J.H., Consequential late effects in normal tissues. Radiother Oncol 61 (2001), 223–231.
37. [37] Hamstra, D.A., Stenmark, M.H., Ritter, T., et al. Age and comorbid illness are associated with late rectal toxicity following dose-escalated radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys 85 (2013), 1246–1253.
38. [38] Tucker, S.L., Dong, L., Bosch, W.R., et al. Late rectal toxicity on RTOG 94-06: analysis using a mixture Lyman model. Int J Radiat Oncol Biol Phys 78 (2010), 1253–1260.
39. [39] Wolf, F., Gaisberger, C., Ziegler, I., et al. Comparison of two different rectal spacers in prostate cancer external beam radiotherapy in terms of rectal sparing and volume consistency. Radiother Oncol 116 (2015), 221–225.
40. [40] Langendijk, J.A., Lambin, P., De Ruysscher, D., Widder, J., Bos, M., Verheij, M., Selection of patients for radiotherapy with protons aiming at reduction of side effects: the model-based approach. Radiother Oncol 107 (2013), 267–273.
41. [41] Lambin, P., Zindler, J., Vanneste, B.G., et al. Decision support systems for personalized and participative radiation oncology. Adv Drug Deliv Rev, 2016 Jan Epub ahead of print.
42. [42] Cheng, Q., Roelofs, E., Ramaekers, B.L., et al. Development and evaluation of an online three-level proton vs photon decision support prototype for head and neck cancer - Comparison of dose, toxicity and cost-effectiveness. Radiother Oncol 118 (2016), 281–285.